Compare Ascendis Pharma A/S (ASND) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Ascendis Pharma A/S trades at $257 (market cap $16.67B), while Direxion Daily Semiconductor Bull 3X Shares trades at $142.88. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| ASND | SOXL | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $300.77 |
52-Week Low | $189.74 | $24.91 |
Enterprise Value | $17.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
SOXL, the Direxion Daily Semiconductor Bull 3X Shares ETF, surged 9.35% to $142.16 amid renewed semiconductor sector optimism. The ETF remains in a technical bearish trend despite the daily rally, with moving averages signaling caution. Recent news highlights significant government semiconductor funding and AI-driven demand catalysts, though the leveraged structure amplifies volatility risks. Financial ratios are unavailable as this is a leveraged ETF tracking semiconductor stocks rather than a traditional company.
SOXL offers aggressive exposure to semiconductor sector rebounds but carries elevated risk due to 3x daily leverage. The current technical setup suggests caution despite positive sentiment around AI chip demand. Key risks include sector volatility, leverage decay, and geopolitical tensions affecting semiconductor supply chains. Investors should understand the specialized nature of leveraged ETFs before considering positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
